Vicarious Surgical (RBOT)

Executive Summary

Vicarious Surgical is a next-generation medical robotics company developing a single-port robotic system for minimally invasive abdominal surgery. The Vicarious Surgical System features a unique design that allows the surgeon to virtually step inside the patient, providing immersive 3D visualization and human-like instrument control through a single incision. Founded in 2014 and headquartered in Waltham, Massachusetts, the company went public via SPAC merger in 2021 and trades under the ticker RBOT. The technology aims to address limitations of current multi-port robotic systems by reducing invasiveness, improving dexterity, and potentially lowering costs. The company is currently in the pre-commercial stage, having conducted first-in-human studies and working toward FDA clearance. Vicarious Surgical targets the large and growing market for robotic-assisted surgery, which is dominated by Intuitive Surgical's da Vinci system. The company's disruptive single-port approach could capture market share in procedures such as cholecystectomy, hernia repair, and colectomy. However, Vicarious faces significant regulatory hurdles, cash burn, and competition from both established players and emerging robotic platforms. The company's success hinges on completing clinical trials, gaining FDA approval, and achieving commercial adoption. Given these factors, conviction in the opportunity is moderate.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance or De Novo Classification40% success
• Q2 2026Pivotal Clinical Trial Results50% success
• TBDStrategic Partnership or Licensing Deal30% success